---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-24-001628"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2024-09-26T23:59:59+00:00"
generated_at: "2026-05-31T01:27:02.965841+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vivani Medical gets Australian approval to start first-in-human GLP-1 implant trial LIBERATE-1

## Summary
- Approval from Bellberry HREC and TGA acknowledgement for LIBERATE-1 trial in obese/overweight subjects.
- Trial will evaluate safety, tolerability, and PK of exenatide NanoPortal implant in 24 participants.
- Preclinical data suggests comparable efficacy to semaglutide with twice-yearly dosing.
- Enrollment expected Q4 2024; data projected in 2025; Australian R&D incentives may defray costs.
- Data intended to support regulatory submissions in the US and other geographies.

## SEC filing metadata
- accession: 0001753926-24-001628
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2024-09-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001628/0001753926-24-001628-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392624001628/vani-20240926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-24-001628
- JSON: https://secwatch.observer/filing/0001753926-24-001628.json
- Plain text: https://secwatch.observer/filing/0001753926-24-001628.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.